-+ 0.00%
-+ 0.00%
-+ 0.00%

Grifols unit GigaGen posts positive Phase 1 data for anti-CTLA-4 candidate GIGA-564

PUBT·04/17/2026 19:03:25
Listen to the news
Grifols unit GigaGen posts positive Phase 1 data for anti-CTLA-4 candidate GIGA-564
  • Grifols unit GigaGen reported positive Phase 1 data for GIGA-564, a non-blocking anti-CTLA-4 antibody, in advanced solid tumors.
  • Safety profile remained favorable, with 1 dose-limiting toxicity reported in 26 treated patients as of Jan. 28, 2026.
  • Efficacy signals included 2 partial responses among 22 evaluable patients; disease control rate reached 50%.
  • NIH/NCI is running trial under a CRADA, with dose escalation completed up to 20 mg/kg every three weeks without reaching maximum tolerated dose.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grifols SA published the original content used to generate this news brief on April 17, 2026, and is solely responsible for the information contained therein.